scispace - formally typeset
A

Allen John Lovey

Researcher at Hoffmann-La Roche

Publications -  44
Citations -  3003

Allen John Lovey is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Cancer & Cyclin-dependent kinase. The author has an hindex of 12, co-authored 44 publications receiving 2857 citations.

Papers
More filters
Journal ArticleDOI

9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha.

TL;DR: The identification of a stereoisomer of retinoic acid, 9-cis retinol, which directly binds and activates RXRα, which suggests a new role for isomerization in the physiology of natural retinoids.
Journal ArticleDOI

Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids

TL;DR: 9-cis forms of endogenous retinoid can contribute to the pleiotropic effects of retinoids by interacting with both the RARs and RXRs.
Journal ArticleDOI

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

TL;DR: RG7112 is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket ofMDM2, which stabilizes p53 and activates the p 53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Journal ArticleDOI

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

TL;DR: Dual MDM2/MDMX antagonists restored p53 apoptotic activity in the presence of high levels of MDMX and may offer a more effective therapeutic modality for MDMX-overexpressing cancers.
Journal ArticleDOI

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.

TL;DR: The 2,4-diamino-5-ketopyrimidines 6 reported here represent a novel class of potent and ATP-competitive inhibitors that selectively target the cyclin-dependent kinase family, and compound 39 demonstrates significant in vivo efficacy in the HCT116 human colorectal tumor xenograft model in nude mice with up to 95% tumor growth inhibition.